Abstract: An engine end cover integrated oil pump assembly comprises an engine end cover, an oil pump, a crankshaft driving gear and a crankshaft driving gear retaining structure. The oil pump comprises a pump body, an oil pump shaft and an oil pump driving gear, wherein the pump body is integrated with the engine end cover, and the oil pump driving gear is connected to the oil pump shaft. The crankshaft driving gear is rotatably arranged on the engine end cover and externally meshes with the oil pump driving gear.

Abstract: An engine end cover integrated oil pump assembly comprises an engine end cover, an oil pump, a crankshaft driving gear and a crankshaft driving gear retaining structure. The oil pump comprises a pump body, an oil pump shaft and an oil pump driving gear, wherein the pump body is integrated with the engine end cover, and the oil pump driving gear is connected to the oil pump shaft. The crankshaft driving gear is rotatably arranged on the engine end cover and externally meshes with the oil pump driving gear.

Abstract: The present application discloses a high-barrier polyolefin composite film, including, from the outside to the inside, an outer PE film, a water-barrier layer, a high-barrier PVA coating layer, an adhesive layer, and an inner PE film, wherein the inner PE film comprises the following raw materials in percentage by weight: 10-20% of HDPE, 30-50% of MDPE, 20-26% of LLDPE, 10-20% of LDPE, 8-12% of a water- and oxygen-barrier masterbatch, and 1-3% of an auxiliary agent; the water- and oxygen-barrier masterbatch includes the following raw materials in parts by weight: 10-20 parts of polycarbonate, 0.1-0.3 parts of a compatibilizer, 10-20 parts of an ethylene-vinyl acetate copolymer (EVA), 1-2 parts of single-layer graphene, and 1-2 parts of polyhedral oligomeric silsesquioxane.

Abstract: A compound serving as a thyroid hormone ? receptor agonist and uses of the compound, also provided is a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition is applicable in preparing a medicament for preventing, treating, or alleviating thyroid hormone ? receptor agonist-modulated diseases, and specifically applicable in preparing a medicament for treating nonalcoholic fatty liver disease.

Abstract: Disclosed is a split continuous operation micro-grid dynamic membrane bioreactor. The split continuous operation micro-grid dynamic membrane bioreactor comprises a biological treatment unit and a drum dynamic membrane filtration unit, wherein the biological treatment unit comprises a microbiological treatment tank, and a water inlet pipe is arranged on the microbiological treatment tank; the drum dynamic membrane filtration unit comprises a filter tank, and a drum micro-grid dynamic membrane mechanism is arranged in the filter tank; the drum micro-grid dynamic membrane mechanism comprises a filter drum, a backwashing device is arranged above the filter drum, and a sludge collecting tank is arranged in the filter drum; a water outlet is formed in the bottom of the filter tank; a mixed liquid pipe is arranged between the microbiological treatment tank and the filter drum; and a sludge discharge header pipe is arranged on the sludge collecting tank.

Abstract: A chemical compound as a thyroid hormone Beta receptor agonist and a use thereof, further including a pharmaceutical composition containing the chemical compound. The chemical compound or pharmaceutical composition can be used in the preparation of drugs for preventing, treating or mitigation of diseases mediated by agonistic thyroid hormone ? receptor, particularly for the preparation of drugs for treating non-alcoholic fatty liver diseases.

Abstract: An isoquinolinone compound acts as an inhibitor of semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1), and the use thereof, and further relates to a pharmaceutical composition containing the compound. The compound or the pharmaceutical composition can be used to prepare a drug for preventing, treating or ameliorating inflammation and/or inflammation-related diseases, diabetes and/or diabetes-related diseases in patients, and especially can be used to prepare a drug for preventing, treating or ameliorating non-alcoholic fatty liver diseases in patients.

Abstract: An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.

Abstract: Disclosed is a split type continuous operation micro-grid dynamic membrane bioreactor. The split type continuous operation micro-grid dynamic membrane bioreactor comprises a biological treatment unit and a drum type dynamic membrane filtration unit, wherein the biological treatment unit comprises a microbiological treatment tank, and a water inlet pipe is arranged on the microbiological treatment tank; the drum type dynamic membrane filtration unit comprises a filter tank, and a drum micro-grid dynamic membrane mechanism is arranged in the filter tank; the drum micro-grid dynamic membrane mechanism comprises a filter drum, a backwashing device is arranged above the filter drum, and a sludge collecting bank is arranged in the filter drum; a water outlet is formed in the bottom of the filter tank; a mixed liquid pipe is arranged between the microbiological treatment tank and the filter drum; and a sludge discharge header pipe is arranged on the sludge collecting tank.

Abstract: An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.